Expert opinion on investigational drugs · 2009
Tesamorelin, a human growth hormone releasing factor analogue.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Ying, Tomlinson Brian
Аннотация
BACKGROUND: The combination of clinical effectiveness with a variety of adverse side effects from the use of recombinant human growth hormone (rhGH) in therapy for growth hormone (GH)-deficient disorders has led to the development of human growth hormone releasing factor (GFR) analogues, which may be better tolerated. Tesamorelin, a synthetic GFR, has been developed as a potential treatment for a variety of conditions that may be associated with a relative deficiency of GH including HIV-related lipodystrophy.
OBJECTIVE: This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications.
METHODS: Relevant articles and abstracts were obtained from searches of the medical and chemical literature databases and the references from published articles.
RESULTS/CONCLUSION: A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. Other potential indications for tesamorelin appear less promising from the current data.
OBJECTIVE: This article reviews the development of tesamorelin and its purported role in HIV-related lipodystrophy and other potential indications.
METHODS: Relevant articles and abstracts were obtained from searches of the medical and chemical literature databases and the references from published articles.
RESULTS/CONCLUSION: A multicenter, randomized, placebo-controlled, Phase III clinical trial suggested that tesamorelin might be a beneficial treatment strategy for HIV-related lipodystrophy with a good safety profile and a positive effect on reducing visceral fat. Other potential indications for tesamorelin appear less promising from the current data.